New hope for lung scarring: TDI01 drug trial begins
NCT ID NCT07464912
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called TDI01 for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 508 adults in China will receive either TDI01 or a placebo to see if the drug helps slow lung function decline over 24 to 52 weeks. The goal is to improve breathing and delay worsening of the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100023, China
Contact Phone: •••-•••-•••• Email: •••••@•••••